Previous 10 | Next 10 |
ANN ARBOR, Mich., April 19, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, May 3, 2022. Following the release, company management will host a webcast and co...
ANN ARBOR, Mich., April 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from a pooled analysis of patients enrolled in four Phase 3 bempedoic acid studies in the Journal of Clinical Lipidology . The paper, “Efficacy and safety of...
ANN ARBOR, Mich., April 03, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL ® ) at the American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22)....
ANN ARBOR, Mich., March 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Needham 21 st Annual Healthcare Conference on Tuesday, April 12, 2022. Live audio webcasts of these e...
The commercial-stage pharma company, Esperion Therapeutics (NASDAQ:ESPR) announced on Tuesday that the company’s Chief Financial Officer Richard B. Bartram was stepping down from his positions effective April 08. In addition to his role as CFO, Bartram also functioned as principal fina...
Gainers: Incannex Healthcare Limited (NASDAQ:IXHL) +271%. Esperion Therapeutics (NASDAQ:ESPR) +10%. GitLab (NASDAQ:GTLB) +9%. Niu Technologies (NASDAQ:NIU) +7%. Lordstown Motors (NASDAQ:RIDE) +6%. Losers: Coupa Software Incorporated (NASDAQ:COUP) -29%. AnaptysB...
H.C. Wainwright has started the coverage on Esperion Therapeutics (ESPR +2.7%) with a Buy recommendation on Thursday, citing the commercial-stage pharma company’s lead products Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe). The oral non-statin cholesterol-loweri...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Esperion Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Esperion Therapeutics recently reported their Q4 and full-year 2021 earnings. NEXLETOL and NEXLIZET together secured $12.2M in U.S. net product revenue, which is up 200% for the year. The company revealed improved commercial metrics including that scripts increased 9% over Q3 and that...
ANN ARBOR, Mich., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Chief Medical Officer, Dr. JoAnne Foody, will participate in a Cardiometabolic/NASH focused panel, in addition to one-on-one investor meetings with other members of management, at the upcoming C...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...